Technology
Health
Pharmaceutical
Arcturus Therapeutics
$6.509876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$6.50
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.22 (3.53%) Today
+$0.05 (0.78%) After Hours
Why Robinhood?
You can buy or sell ARCT and other stocks, options, ETFs, and crypto commission-free!
About
Arcturus Therapeutics Ltd. engages in the provision of RNA medicines, which focuses on liver and respiratory diseases. Its RNA medicines include mRNA; siRNA, miRNA, and ASO;, CRISPR, TALEN, and meganucleases; and Replicon RNA and DNA. Read More The company was founded by Joseph Payne in March 2013 and is headquartered in San Diego, CA.
Employees
—
Headquarters
San Diego, California
Founded
2013
Market Cap
69.14M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
33.99K
High Today
$6.35
Low Today
$6.22
Open Price
$6.30
Volume
6.37K
52 Week High
$10.00
52 Week Low
$4.11
Collections
Technology
Health
Pharmaceutical
Therapy
2013 IPO
US
North America
News
Yahoo FinanceMay 13
Arcturus Therapeutics Announces First Quarter Financial Results and Provides a Corporate Update
SAN DIEGO, May 13, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today reported its financial results for the quarter ended March 31, 2019 and provided a corporate update. “We are pleased with our progress in 2019, as we continue to work to strengthen our leadership position in intravenous and inhaled mRNA medicines,” said Joseph Payne, President & CEO of ...
Price Paid on Robinhood
24% Lower
Right Now
52 Week Low
$4.11
Average Price Paid
$8.53
52 Week High
$10.00
Earnings
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected May 13